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ABSTRACT
Annual vaccination is the most effective way to prevent seasonal influenza illness. 
Instituto Butantan (IB) performed clinical studies with its 2013, 2014 and 2015 seasonal 
trivalent influenza vaccines (inactivated split-virion). Prospective cohort studies were carried 
out to describe the safety and immunogenicity of Instituto Butantan influenza vaccines, in 
healthy adults and elderly, from 2013 to 2015. Immediately after the informed consent was 
signed, participants underwent blood collection followed by vaccination. On study days 1, 
2 and 3 post-vaccination participants were contacted by the staff to evaluate the occurrence 
of solicited (local and systemic) and non-solicited adverse reactions. On study day 21 (+7) 
subjects returned to the clinical site for final safety assessments and blood collection to 
evaluate post-vaccination immunogenicity. The immunogenicity analyses were performed 
by means of hemagglutination inhibition (HI) assay. The immunogenicity endpoints were: 
seroprotection (SPR) and seroconversion (SCR) rates and the geometric mean HI antibody 
titer ratio (GMTR). The 2013 study was conducted at the Centro de Referência para 
Imunobiológicos Especiais (CRIE) and at the Centro de Pesquisa Clínica do Instituto da 
Criança, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 
while the 2014 and 2015 studies were conducted at CRIE. The vaccine composition followed 
the WHO recommendation for the Southern hemisphere seasonal influenza vaccine. Forty-
seven healthy adults and 13 elderly participated in the 2013 study, 60 healthy adults and 60 
elderly in the 2014 study, and 62 healthy adults and 57 elderly in the 2015 study. In the 2013, 
2014 and 2015 studies, pain was the most frequent local adverse reaction and headache the 
most frequent systemic adverse reaction. All observed adverse reactions were classified as 
mild or moderate and none as severe. SPR >70% and SPR >60% were observed in adults 
and elderly, respectively, for the three vaccine viruses, in the 2013, 2014 and 2015 studies. 
SCR >40% was observed in adults, for the three vaccine viruses, only in the 2014 study and 
SCR >30% was observed in the elderly, for the three vaccine viruses, only in the 2013 and 
2014 studies. GMTR >2.5 among adults, for the three vaccine viruses was only observed in 
the 2013 study and GMTR >2.0 was observed among elderly, for the three vaccine viruses, 
in the 2013, 2014 and 2015 studies. The 2013, 2014 and 2015 seasonal influenza vaccines 
produced by Instituto Butantan were safe and immunogenic according to the immunogenicity 
criteria defined by the European Medicines Agency (EMA).
KEYWORDS: Seasonal influenza vaccine. Vaccine immunogenicity. Vaccine safety. Cohort 
studies. Adults. Elderly.
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INTRODUCTION
Influenza or Flu is a viral disease of high transmissibility 
that affects the respiratory tract of people at any age and 
has global distribution. According to the World Health 
Organization (WHO), this disease results in 3 to 5 million 
of serious cases and 250,000 to 500,000 deaths, annually1.
People at increased risk to develop complications 
associated with influenza virus include adults older than 
65 years, pregnant women, immunocompromised patients, 
people with chronic underlying medical conditions, children 
under 5 years of age and health care professionals2,3. 
Annual vaccination is recommended by WHO as the most 
effective way of preventing seasonal influenza. In Brazil, 
the National Immunization Program (NIP) of the Ministry 
of Health has carried out annual national influenza vaccine 
campaigns since 1999. In the first national immunization 
campaign, the NIP recommended vaccination only for adults 
over 65 years of age, however, the recommendation has 
progressively been expanded to other target groups such as 
children 6 months to 5 years, adults over 60 years, pregnant 
women, women in the post-partum period (up to 45 days), 
healthcare professionals, indigenous people, people from 12 
to 21 years under socio-educational programs (adolescents 
being followed in freedom or not for different kind of 
conflicts with law), people deprived of freedom, employees of 
the prison system, people with chronic and/or other medical 
conditions4. In Brazil, the NIP has provided the inactivated 
split-virion seasonal trivalent influenza vaccine (inactivated 
split-virion) free of charge to the target populations5.
Instituto Butantan (IB) is a public Brazilian biomedical 
research manufacturer center affiliated to the Sao Paulo 
State Secretary of Health. Currently, it is one of the main 
public producers of vaccines, antivenoms, and antitoxins 
in Latin America.
From 2013 to 2015, the IB’s Division of Clinical Trials 
and Pharmacovigilance performed prospective cohort studies 
to evaluate the safety and immunogenicity of the 2013, 2014, 
and 2015 seasonal trivalent influenza vaccines (inactivated 
split-virion) in health adults and people over 60 years of 
age. Here, we describe the results of those studies, which 
were requested by the Brazilian regulatory health authority 
(Agência Nacional de Vigilância Sanitária – ANVISA).
MATERIAL AND METHODS
Study designs
In 2013, 2014, and 2015 we performed prospective 
cohort studies. The 2013 study was conducted at the Centro 
de Referência de Imunobiológicos Especiais (CRIE) and 
at the Centro de Pesquisa Clínica do Instituto da Criança 
(ICR) both from the Hospital das Clínicas da Faculdade 
de Medicina da Universidade de São Paulo (HCFMUSP). 
However, the 2014 and 2015 studies were conducted 
exclusively at CRIE. The three studies were performed 
within the period of the Brazilian national immunization 
campaign for influenza, and all were approved by the Ethics 
Committee of the Faculdade de Medicina da Universidade 
de São Paulo and were registered at ClinicalTrials.gov 
(2013 study: NCT02819115, 2014 study: NCT02819180, 
and 2015 study: NCT 02313740). The three studies 
were conducted in accordance with the principles of 
the Declaration of Helsinki, Good Clinical Practices6, 
Resolution 466/2012 of the Brazilian National Health 
Council (CNS) on ethics in human research and financially 
sponsored by Butantan Foundation.
Subjects and study procedures
Healthy, male and non-pregnant female between 18 
and 59 years of age, and elderly over 60 years of age were 
eligible for enrollment and the participants were selected 
based on inclusion and exclusion criteria (described 
below). All participants provided written informed consent 
and were invited to participate at the time they presented 
spontaneously at the clinic where the study was taking place. 
These predefined age groups followed the recommendation 
by the European Medicines Agency (EMA) for studies of 
seasonal influenza vaccines7,8.
Inclusion criteria:
1. Healthy adults, male or female aged 18 to 59 or elderly 
aged 60 years and above;
2. To be available to participate in the study throughout 
its duration (approximately 21 days);
3. To have medical indication to be vaccinated against 
influenza;
4. To demonstrate intention to participate in the study, as 
documented by the signature in the study’s informed 
consent form (ICF).
Exclusion criteria:
1. Evidence of active neurological, cardiac, pulmonary, 
hepatic or renal disease as clinical history and/or 
physical examination (except hypertension under 
control among the elderly);
2. Compromised immune system diseases including: HIV, 
diabetes mellitus, cancer (except basal cell carcinoma) 
and autoimmune diseases;
3. Behavioral, cognitive or psychiatric disease that in the 
opinion of the principal investigator or his representative 
physician, affects the participant ability to understand 
and cooperate with all study protocol requirements;
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4. Alcohol or drugs abuse in the past 12 months that 
has caused medical, professional or family problems, 
indicated by clinical history;
5. Known systemic hypersensitivity to eggs or to any 
component of the vaccine;
6. History of severe adverse reaction after previous 
administration of an Influenza vaccine within 6 weeks 
following vaccination;
7. History of Guillain-Barré Syndrome or other 
demyelinating disease;
8. Diagnosis of asthma with a history of hospitalization in 
the last six months due to the illness;
9. Suspected or confirmed fever in the 3 days prior to 
vaccination or axillary temperature greater than 37.8 °C 
on the day of vaccination;
10. Use of corticosteroids (except topical or nasal) or 
other immunosuppressive drugs within 42 days before 
the study initiation/baseline. It will be considered 
immunosuppressive dose of corticosteroids the equivalent 
to a dose ≥ 10 mg of prednisone per day for over 14 days;
11. Impaired coagulation due to chronic disease or due to 
the use anticoagulant medication (warfarin or heparin) 
in the 7 days preceding vaccination;
12. Have received live virus vaccine within 28 days or killed 
virus vaccine in the last 14 days prior to vaccination, 
or having a scheduled immunization during the first 
21 days after vaccination;
13. Have received influenza vaccine in the past 6 months;
14. History of asplenia;
15. Have received blood products in the past 6 months, 
including transfusions or immunoglobulin, or scheduled 
administration of blood products or immunoglobulin for 
the first 21 days after vaccination;
16. have a counter indication for Influenza vaccination, 
including allergy to egg proteins;
17. Use of any investigational product within 42 days before 
vaccination;
18. Any other condition that might put in risk the safety/
rights of a potential participant or hurdle his/her 
compliance with this protocol in the investigator’s 
opinion or his representative physician.
Procedures
Participants were included in the study soon after 
their inclusion, exclusion criteria were checked and the 
informed consent signed. A blood sample of 5 ml was taken 
before vaccination and on day 21 (+7) post-vaccination 
(for immunogenicity analysis). Participants received one 
dose of the vaccine intramuscularly and were observed for 
30 min at the research clinical site. Before leaving, they 
were oriented to take the axillary temperature and record 
it in the participant card for the following three days. 
Fever was defined as an axillary temperature ≥37.8 ºC. 
Participants were also contacted by telephone three days 
after vaccination to check the occurrence of any unsolicited 
and solicited local (pain, bruising, redness, and swelling), 
and systemic (fever, chills, myalgia, fatigue, and headache) 
adverse reactions (AR). On day 21 (+7) post-vaccination 
participants returned to the research clinic for the post-




The primary safety endpoints were solicited and 
unsolicited local and systemic adverse reactions reported 
by the participants until day 3 after vaccination. Adverse 
reactions were defined as adverse events that had reasonable 
causal relationship to vaccination, as defined by the adapted 
classification of “Uppsala Monitoring Centre” of the World 
Health Organization9. The intensity of adverse reactions 
was classified as grade one to four according to the Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers 
Enrolled in Preventive Vaccine Clinical Trials of the US 
Food and Drug Administration (FDA)10.
Immunogenicity endpoints
The three co-primary immunogenicity endpoints were 
the proportion of participants that presented seroconversion 
(pre-vaccination hemagglutination inhibition (HI) 
antibody titer <1:10 and post-vaccination HI antibody 
titer ≥1:40, or pre-vaccination HI antibody titer <1:10 and 
a post-vaccination increase by a factor of four or more), 
the proportion of participants with seroprotection (post-
vaccination HI antibody titer ≥1:40), and the factor increase 
in the geometric mean titer, all measured before and 21 days 
after each vaccination. 
The immunological criteria for evaluation of influenza 
vaccines were based on the Note for Guidance on 
Harmonization of Requirements for Influenza Vaccines of 
“The European Medicines Agency (EMA)”7. According 
to EMA a seasonal influenza vaccine is considered 
immunogenic when one of the immunogenicity endpoints is 
demonstrated accordingly with the age7. The immunological 
criteria for the evaluation of seasonal influenza vaccines are 
described in Table 1.
Laboratory assays
Anti-influenza antibody response was measured by the 
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hemagglutination-inhibition assay, according to standard 
method at Adolfo Lutz Institute (IAL) (Sao Paulo, Brazil). 
Titers were tested at an initial dilution of 1:10, and at a final 
dilution of 1:2,560. For the purposes of calculation, negative 
titers were assigned a value of 1:5 and those with titers 
above 1:2,560 had assigned a value of 1:2,560. Samples 
were tested in duplicate, and the geometric mean value was 
used in the analyses7,11. 
Vaccines
The composition of seasonal trivalent influenza 
vaccines (inactivated split-virion) produced by IB and 
evaluated in this study followed the WHO composition 
recommendation for the Southern Hemisphere. Their 
compositions were: 2013 (A/California/7/2009 (H1N1)
pdm09-like virus; A/Victoria/361/2011 (H3N2)-like virus 
B/Wisconsin/1/2010-like virus); 2014 (A/California/7/2009 
(H1N1)pdm09-like virus, A/Texas/50/2012 (H3N2)-
like virus, B/Massachusetts/2/2012-like virus), and 
2015 (A/California/7/2009 (H1N1)pdm09-like virus; 
A/Switzerland/9715293/2013 (H3N2)-like virus; 
B/Phuket/3073/2013-like virus. The vaccines were 
formulated in a 10-dose vials (0.5mL per dose) and stored 
at 2-8 ºC until used.
Sample size
The planned sample size for the 2013 study was 100 
participants (50 adults and 50 elderly) and for the 2014 and 
2015 studies, 120 participants (60 adults and 60 elderly). 
These sample sizes were accepted by ANVISA and followed 
the EMA7 recommendation to demonstrate safety and 
immunogenicity of seasonal influenza vaccine. 
Statistical analysis
In this study, we performed a descriptive statistical 
analysis stratified by participants age groups: adults up 
to 59 years and elderly above 60 years. The demographic 
characteristics of the participants were described by 
percentage (gender and ethnicity) and by estimated 
measures of central tendency and dispersion (age). 
For each study year sex, ethnicity and number of 
participants with adverse reactions were compared between 
groups using Chi-square test or Fisher’s exact test.
The safety analysis was described to all participants 
using the percentages of adverse reactions (AR), solicited 
and non-solicited, by age group and study year. These 
frequencies were compared by the Chi-square test or the 
Fisher’s exact test. 
The immunogenicity endpoints were analyzed for each 
age group, by influenza vaccine strain and study year. In 
the immunogenicity analysis, only participants with pre and 
post-vaccination blood samples available were included.
The geometric mean HI antibody titer, pre- and post-
vaccination, and the GMTR were calculated with respective 
95% confidence intervals (CI). The SCR, SPR and the 
proportion of participants with pre-vaccination HI antibody 
titer ≥1:40 were also calculated with the respective 95% CI. 
To each age group, by study year and influenza vaccine 
strain the percentages of SCR, SPR and the GMTR were 
calculated stratified by pre-vaccination HI antibody titer 
results (<1:40 or ≥1:40). The Mann-Whitney test was used 
to assess the significance of differences in GMTR between 
strata. SCRs were compared using the the Fisher’s exact test.
Statistical analyses were performed using a significance 
level of 5%. The software Stata 13.0 (StataCorp LP, College 
Station, Texas USA) was used in the analyses.
RESULTS
Study participants
The 2013, 2014, and 2015 studies were performed 
from June 4 to July 27th, April 22nd to June, and May 23rd 
to June 23rd, respectively. The participant demographic 
characteristics are described in Table 2. The total number 
of participants included in the safety and immunogenicity 
analysis is described in Figure 1.
In 2013, 63 volunteers agreed to participate in the study 
and signed the informed consent (63% of the planned 
sample size): 50 adults and 13 elderly. However, only 47 
(94%) adults were included in the safety analysis, since 
two of them had been vaccinated with an influenza vaccine 
not produced by IB and one participant presented with 
high blood pressure on the vaccination day and, therefore, 
was not vaccinated. The median age of the adults was 33.3 
years, and the elderly 67.8 years. Only 13 (26%) of the 
elderly participants agreed to participate in the study and 
signed the informed consent and all were included in the 
safety analysis.
In 2014, 120 volunteers agreed to participate in the study 
Table 1 - Immunological criteria for the evaluation of seasonal 
influenza vaccines
Parameters – one or more of the 
following: 




Seroconversion rate (SCR) >40% >30%
Geometric mean titer ratio (GMTR) >2.5 >2.0
Seroprotection rate (SPR) >70% >60%
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and signed the informed consent. All of them were included 
in the safety analysis. The median age of the adults was 30.1 
years and the elderly 66.9 years. 
In 2015, 120 agreed to participate in the study and 
signed the informed consent, however, only 119 (99.2%) 
were included in the safety analysis, 62 adults and 57 
elderly. One participant was excluded from safety analysis 
because he was vaccinated with an influenza vaccine not 
produced by IB. The median age of the adults was 31.5 and 
the elderly 68.3 years.
Safety data
Table 3 shows the descriptive statistical analysis of the 
adverse reactions according to study year and age group. 
Table 4 shows the descriptive statistical analysis of the local 
and systemic solicited and non-solicited adverse reactions, 
by study year and age group.
In the 2013 study, the total number of adult and elderly 
participants with ARs was 24 (51%) and four (30.8%), 
respectively. There was no significant statistical difference 
in the incidence of ARs between adults and elderly 
(p=0,226). The total number of ARs was 40, 34 (85%) 
in adults and six (15%) in the elderly. The mean number 
of ARs was 1.4 per adult and 1.5 per elderly. Thirty-two 
(94.1%) out of 34 ARs observed in adults were classified 
as grade I (mild) and two (5.9%) as grade II (moderate). 
All adverse reactions reported by the elderly were classified 
as grade I (mild). The mean interval between the time of 
vaccination and the onset of ARs in adults was 1.2 days and 
in the elderly 0.3 days. The mean duration of the ARs among 
adults was one day and among the elderly 6.5 days. Pain 
at the injection site and headache were the most frequent 
solicited, local and systemic ARs in both adults and elderly. 
































Sex (n (%))  0.045 0.845  0.725
Female 29 (61.7) 12 (92.3)  41 (68.3) 40 (66.7)  40 (64.5) 35 (61.4)
Male 18 (38.3) 1 (7.7)  19 (31.7) 20 (33.3)  22 (35.5) 22 (38.6)
Ethnicity (n (%))  0.159*** 0.001***  0.977***
White 38 (80.8) 8 (61.5)  42 (70.0) 24 (40.0)  48 (77.4) 44 (77.2)
Black 2 (4.3) -  4 (6.7) 2 (3.3)  1 (1.6) 2 (3.5)
Multirracial 3 (6.4) 1 (7.7)  1 (1.7) 1 (1.7)  9 (14.5) 2 (3.5)
Asian 4 (8.5) 2 (15.4)  4 (6.6) 2 (3.3)  4 (6.5) 8 (14.0)
Other - 2 (15.4)  9 (15.0) 31 (51.7)  - 1 (1.8)  
NA: Not Applicable; (*) Fisher´s exact test; (**) Chi-square test; (***) white x others
Figure 1 - Flowchart with the number of participants included 
and analyzed by the study endpoints, year and age group
Mondini et al.
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N of participants with 
ARs
24 (51.0%) 4 (30.8%) p=0.226* 41 (68.3%) 16 (26.7%) p<0.001** 33 (53.2%) 16 (28.1%) p=0.005**
N of ARs 34 6 85 25  61 34
N of ARs per 
participant***
    
mean (sd) 1.4 (0.7) 1.5 (0.6) 2.1 (1.4) 1.6 (1.2)  1.8 (1.5) 2.1 (1.8)
median (min-max) 1 (1 - 3) 1.5 (1 - 2) 1 (1 - 5) 1 (1 - 5)  1 (1 - 8) 1.5 (1 - 7)
ARs grade/intensity     
1 32 (94.1%) 6 (100%) 85 (100%) 25 (100%) 49 (80.3%) 24 (70.6%)
2 2 (5.9%) - - -  12 (19.7%) 10 (29.4%)
AR onset (days) from 
vaccination
    
mean (sd) 1.2 (0.9) 0.3 (0.8) 0.4 (0.6) 0.6 (0.9)  0.8 (0.8) 0.4 (0.8)
median (min-max) 1 (0 - 3) 0 (0 - 2) 0 (0 - 3) 0 (0 - 3)  1 (0 - 3) 0 (0 -3)
ARs duration (days)     
mean (sd) 1.0 (2.2) + 6.5 (9.3) ++ 1.9 (1.2) 2.0 (1.2)  1.4 (4.4) 1.1 (1.0)
median (min-max) 0 (0 - 12)+ 3 (0 - 20)++  2 (0 - 7) 2 (0 - 6)  1 (0 - 34) 1 (0 - 3)  
Abbreviation: AR, adverse reaction. (*) Fisher´s exact test; (**) Chi-square test; (***) Among those who presented AR. (+) 4 ARs 
with missing data, (++) 2 ARs with missing data.
Table 4 - Local and systemic solicited and non-solicited adverse reactions according to the study year and age group
Adverse Reactions














Local    
Pain 15 (31.9) 2 (15.4) 0.314 40 (66.7) 12 (20.0) <0.001 29 (46.8) 13 (22.8) 0.007
Erythema 1 (2.1) - 0.596 - - - 1 (1.6) 2 (3.5) 0.606
Swelling - - - 2 (3.3) - 0.496 4 (6.5) 2 (3.5) 0.681
Induration 1 (2.1) - 0.296 6 (10.0) 3 (5.0) 0.491 3 (4.8) 1 (1.8) 0.620
Ecchymosis - 1 (7.7) 0.217 2 (3.3) 1 (1.7) >0.999 1 (1.6) 1 (1.8) >0.999
Systemic    
Fever 3 (6.4) - 0.350 1 (1.7) 2 (3.3) >0.999 3 (4.8) 3 (5.3) >0.999
Chills 1 (2.1) - 0.596 5 (8.3) - 0.057 1 (1.6) 3 (5.3) 0.348
Headache 4 (8.5) 1 (7.7) 0.925 11 (18.3) 3 (5.0) 0.086 7 (11.3) 4 (7.0) 0.533
Fatigue - - - 8 (13.3) 2 (3.3) 0.047 2 (3.2) 1 (1.8) >0.999
Myalgia - - - 10 (16.7) 2 (3.3) 0.029 5 (8.1) 2 (3.5) 0.442
Unsolicited reactions
Sore throat 2 (4.2) - >0.999 - - - - - -
Cough 3 (6.4) - >0.999 - - - - - -
Rhinorrhoea 3 (6.4) 1 (7.7) >0.999 - - - - - -
Dry mouth - - - - - - 1 (1.6) - >0.999
Arthralgia - - - - - - 1 (1.6) - >0.999
Insonmnia - - - - - - 1 (1.6) - -
Nausea - - - - - - - 1 (1.8) 0.479
Pruritus 1 (2.1) 1 (7.7) 0.389 - - - - - -
Local Pruritus - - - - - - 2 (3.2) 1 (1.8) >0.999
(*) Fisher´s exact test; (**) Chi-square test
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There was no significant statistical difference with respect 
the incidence of local and systemic solicited ARs between 
adults and elderly.
In the 2014 study, the total number of adult and elderly 
participants with ARs was 41 (68.3%) and 16 (26.7%), 
respectively. The incidence of ARs was statistically 
significant higher among adults when compared to elderly 
(p<0.001). The total number of ARs was 110, 85 (77.3%) 
in adults and 25 (22.7%) in the elderly. The mean number 
of ARs was 2.1 per adult and 1.6 per elderly. All the ARs 
observed in adults and elderly were classified as grade I 
(mild). The mean interval between the time of vaccination 
and the onset of ARs in adults was 0.4 days and in the elderly 
0.6 days. The mean duration of the ARs among adults was 
1.9 day and among elderly 2.0 days. Pain at the injection 
site and headache were the most frequent solicited, local 
and systemic ARs in both adults and elderly. Pain at the 
injection site (p<0.001), fatigue (p<0.047) and myalgia 
(p<0.029) were statistically more frequent in adults when 
compared to elderly.
In the 2015 study, the total number of adult and elderly 
participants was 33 (53.2%) and 16 (28.1%), respectively. 
The incidence of ARs was statistically significant higher 
among adults when compared to elderly (p=0.005). The 
total number of ARs was 95, being 61 (64.2%) in adults and 
34 (35.8%) in the elderly. The mean number of ARs was 
1.8 per adult and 2.1 per elderly. Forty-nine (80.3%) out of 
61 ARs observed in adults were classified as grade I (mild) 
and 12 (19.7%) as grade II (moderate). Twenty-four (70.6%) 
out of 34 ARs observed in the elderly were classified as 
grade I (mild) and 10 (29.4%) as grade II (moderate). The 
mean interval between the time of vaccination and the 
onset of ARs in adults was 0.8 days and in the elderly 0.4 
days. The mean duration of the ARs among adults was 1.4 
day and among the elderly 1.1 days. Pain at the injection 
site and headache were the most frequent solicited, local 
and systemic ARs in both adults and elderly. Pain at the 
injection site (p<0.007) was statistically more frequent in 
adults when compared to elderly.
Immunogenicity data
Tables 5 and 6 show the immunogenicity results of 2013, 
2014 and 2015 studies.
In the 2013 study, only 55 (91.7%) out of 60 participants 
had pre and post-vaccination blood samples collected, 
therefore were included in the immunogenicity analysis: 
42 adults and 13 elderly. Before immunization, 50% of 
the adults had HI antibodies titers ≥1:40 for H1N1, H3N2, 
and influenza B viruses; among elderly, 53.8% had HI 
antibodies titers ≥1:40 for H1N1 virus and 30.8% for H3N2 
and influenza B viruses (Table 5). In adults SPR >70%, 
SCR >40% and GMTR >2.5 were described for the three 
vaccine viruses (Table 5). Adults with pre-immunization HI 
antibodies titers <1:40 had significantly higher GMTRs for 
the three vaccine antigens when compared to those with pre-
immunization HI antibodies titers ≥1:40 (H1N1: p<0.001; 
H3N2: p=0.023; B: p<0.001) (Table 6).
The SCR for H1N1 vaccine virus was also significantly 
higher among the adults with pre-immunization HI 
antibodies titers <1:40 when compared to those with 
pre-immunization HI antibodies titers ≥1:40 (p<0.001). 
However, there was no significant statistical difference in 
the SCR for H3N2 (p=0.454) and for influenza B (p=0.005) 
vaccine viruses regardless the pre-immunization HI 
antibodies titers (Table 6). In the elderly, SPR >60%, SCR 
>30% and GMTR >2.0 were described for the three vaccine 
viruses (Table 5). The elderly with pre-immunization HI 
antibodies titers <1:40 had significantly higher GMTRs 
for H1N1 and H3N2 vaccine viruses when compared to 
those with pre-immunization HI antibodies titers ≥1:40 
(p<0.009 and p=0.011, respectively) (Table 6). However, 
there was no significant statistical difference in the GMTR 
for influenza B vaccine virus (p=0.337) regardless of the 
pre-immunization HI antibodies titers (Table 6). 
The SCR for the H3N2 vaccine virus was also 
statistically higher among the elderly with pre-immunization 
HI antibodies titers <1:40 when compared to those with 
pre-immunization HI antibodies titers ≥1:40 (p=0.007). 
However, there was no statistically significant difference in 
the SCR for the H1N1 (p=0.192) and influenza B (p=0.530) 
vaccine viruses regardless of the pre-immunization HI 
antibodies titers (Table 6).
In the 2014 study, 115 (95.8%) out of 120 participants 
completed their pre-vaccination and post-vaccination blood 
sample collection and, therefore, were included in the 
immunogenicity analysis: 57 adults and 58 elderly. Before 
immunization, 84.2% of the adults had HI antibodies titers 
≥1:40 for H1N1 virus, 77.2% for H3N2 virus, and 87.7% 
for influenza B virus; among the elderly, 56.9% had HI 
antibodies titers ≥1:40 for H1N1 virus, 81% for H3N2 virus, 
and 74.1% for influenza B virus (Table 5). In adults SPR 
>70% and SCR <40% were described for the three vaccine 
viruses. GMTR >2.5 was only found for H1N1 and H3N2 
vaccine viruses (Table 5). Adults with pre-immunization HI 
antibodies titers <1:40 had significantly higher GMTRs for 
the three vaccine viruses when compared to those with pre 
immunization HI antibodies titers ≥1:40 (H1N1 p=0.011; 
H3N2 p<0.001; influenza B p<0.001) (Table 6). 
The SCR for H3N2 and influenza B vaccine viruses 
were also significantly higher among adults with pre 
immunization HI antibodies titers <1:40 when compared 
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to those with pre immunization HI antibodies titers 
≥1:40 (H3N2 p=0.002; influenza B p=0.001). However, 
there was no significant statistical difference in the SCR 
for H1N1 vaccine virus (p=0.075) regardless of the 
pre-immunization HI antibodies titers (Table 6). In the 
elderly, SPR >60%, SCR >30% and GMTR >2.0 were 
demonstrated for the three vaccine antigens (Table 5). The 
elderly with pre-immunization HI antibodies titers <1:40 
had significantly higher GMTRs for H1N1, H3N2 and 
for influenza B vaccine viruses when compared to those 
with pre-immunization HI antibodies titers ≥1:40 (H1N1: 
p=0.005; H3N2: p<0.011; B: p<0.010) (Table 6). The 
SCR for the three vaccine viruses were also statistically 
higher among the elderly with pre immunization HI 
antibodies titers <1:40 when compared to those with pre 
immunization HI antibodies titers ≥1:40 (H1N1: p=0.016; 
H3N2: p=0.001; B: p=0.013) (Table 6).
In the 2015 study, 115 (96.6%) out of 119 participants 
had pre and post- vaccination blood samples collection, 
therefore, were included in the immunogenicity analysis: 
59 adults and 56 elderly. Before immunization, 78.0% of 
the adults had HI antibodies titers ≥1:40 for H1N1, 57.6% 
for H3N2, and 88.1% for influenza B viruses; among the 
elderly, 39.3% had HI antibodies titers ≥1:40 for H1N1 
virus, 48.2% for H3N2 virus, and 62.5% for influenza B 
virus (Table 5). In adults, SPR >70% was achieved for the 
three vaccine viruses, however, SCR >40% and GMTR >2.5 
were described only for the H3N2 vaccine virus (Table 5). 
Adults with pre-immunization HI antibodies titers <1:40 
had significantly higher GMTRs for the three vaccine 
viruses when compared to those with pre-immunization HI 
antibodies titers ≥1:40 (H1N1: p=0.002; H3N2: p<0.001; 
B: p=0.028) (Table 6). 
The SCR for the three vaccine viruses was also 
significantly higher among adults with pre-immunization 
HI antibodies titers <1:40 when compared to those with pre-
immunization HI antibodies titers ≥1:40 (H1N1: p=0.019; 
H3N2: p=0.001; B: p=0.046) (Table 6). In the elderly, 
SPR >60% and GMTR >2.0 were demonstrated for the 
three vaccine antigens, but SCR >30% only for the H3N2 
and influenza B viruses (Table 5). The elderly with pre-
immunization HI antibodies titers <1:40 had significantly 
Table 5 - Pre- and post-vaccination hemagglutination-inhibition antibodies titers, geometric mean titer ratio, seroprotection and 
seroconversion rates distributed by age group and study year
RESULTS
2013 Study 2014 Study 2015 Study
Adults (n=42) Elderly (n=13) Adults (n=57) Elderly (n=58) Adults (n=59) Elderly (n=56)
(CI 95%) (CI 95%) (CI 95%)
Pre-vaccination
HI ≥1:40       
H1N1 50.0% (34.2 – 65.8) 53.8% (25.1 – 80.8) 84.2% (72.1 – 92.5) 56.9% (43.2 – 69.8) 78.0% (65.3 – 87.7) 39.3% (26.5 – 53.2)
H3N2 50.0% (34.2 – 65.8) 30.8% (9.1 – 61.4) 77.2% (64.2 – 87.3) 81.0% (68.6 – 90.1) 57.6% (44.1 – 70.4) 48.2% (34.7 – 62.0)
B 50.0% (34.2 – 65.8) 30.8% (9.1 – 61.4) 87.7% (76.3 – 94.9) 74.1% (61.0 – 84.7) 88.1% (77.1 – 95.1) 62.5% (48.5 – 75.1)
GMT       
H1N1 31.2 (19.3 – 50.5) 32.3 (13.4 – 77.8) 72.6 (54.2 – 97.2) 31.5 (23.3 – 42.6) 69.5 (53.3 – 90.6) 23.8 (17.9 – 31.5)
H3N2 24.0 (16.1 – 35.8) 23.5 (10.5 – 52.5) 74.4 (51.4 – 107.6) 78.1 (56.5 – 108.0) 33.1 (23.9 – 45.9) 29.0 (22.1 – 38.0)
B 24.8 (17.3 – 35.5) 18.0 (10.8 – 29.9) 180.7 (125.3 – 260.6) 57.9 (44.4 – 75.7) 81.9 (64.8 – 103.6) 38.5 (30.1 – 49.4)
Post-vaccination
GMT       
H1N1 167.0 (119.0 – 234.4) 272.7 (167.3 – 444.4) 187.4 (145.9 – 240.8) 123.0 (94.0 – 160.9) 134.1 (106.2 – 169.5) 59.4 (45.0 – 78.5)
H3N2 230.0 (153.8 – 344.1) 198.0 (99.1 – 395.7) 209.1 (165.3 – 264.5) 231.7 (182.8 – 293.7) 182.1 (140.9 – 235.3) 178.9 (128.6 – 248.7)
B 89.8 (67.2 – 120.0) 80.0 (43.2 – 148.2) 408.1 (305.5 – 545.3) 161.9 (125.6 – 208.8) 143.9 (115.0 – 180.2) 100.0 (78.4 – 127.5)
GMTR       
H1N1 5.4 (3.52 – 8.1) 8.4 (3.8 – 19.0) 2.6 (2.2 – 3.1) 3.9 (3.1 – 5.0) 1.9 (1.6 – 2.4) 2.5 (2.1 – 3.0)
H3N2 9.6 (6.5 – 14.1) 8.4 (3.4 – 21.0) 2.8 (2.1 – 3.7) 3.0 (2.2 – 3.9) 5.5 (4.1 – 7.3) 6.2 (4.7 – 8.2)
B 3.6 (2.7 – 4.8) 4.5 (2.4 – 8.2) 2.3 (1.8 – 2.8) 2.8 (2.2 – 3.5) 1.8 (1.5 – 2.1) 2.6 (2.1 – 3.2)
SCR       
H1N1 57.1% (41.0 – 72.3) 76.9% (46.2 – 95.0) 38.6% (26.0 – 52.4) 48.3% (35.0 – 61.8) 15.3% (7.2 – 27.0) 25.0% (14.4 – 38.4)
H3N2 78.6% (63.2 – 89.7) 61.5% (31.6 – 86.1) 31.6% (19.9 – 45.2) 37.9% (25.5 – 51.6) 72.9% (59.7 – 83.6) 67.9% (54.0 – 79.7)
B 52.4% (36.4 – 68.0) 69.2% (38.6 – 90.9) 17.5% (8.7 – 29.9) 37.9% (25.5 – 51.6) 13.6% (6.0 – 25.0) 39.3% (26.5 – 53.2)
SPR       
H1N1 95.2% (83.8 – 99.4) 100% (75.3 – 100) 96.5% (87.9 – 99.6) 93.1% (83.3 – 98.1) 94.9% (85.9 – 98.9) 66.1% (52.2 – 78.2)
H3N2 95.2% (83.8 – 99.4) 92.3% (64.0 – 99.8) 98.2% (90.6 – 100) 98.3% (90.8 – 100) 98.3% (90.9 – 100) 87.5% (75.9 – 94.8)
B 90.5% (77.4 – 97.3) 92.3% (64.0 – 99.8) 100% (93.7 – 100) 98.3% (90.8 – 100) 96.6% (88.3 – 99.6) 87.5% (75.9 – 94.8)
Abbreviations: GMT, Geometric Mean Titer; GMTR, Geometric Mean Titer Ratio; SCR, Seroconversion Rate; SPR, Seroprotection Rate. 
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higher GMTRs only for the H1N1 and influenza B vaccine 
viruses when compared to those with pre-immunization HI 
antibodies titers ≥1:40 (p=0.044; p=0.014, respectively) 
(Table 6). However, there was no significant statistical 
difference in the GMTR for H3N2 vaccine virus (p=0.053) 
regardless of the pre-immunization HI antibodies titers 
(Table 6). There was no statistically significant difference 
in the SCR, for the three viruses, when one elderly with 
pre-immunization HI antibodies titers <1:40 were compared 
to those with pre-immunization HI antibodies titers ≥1:40 
(H1N1: p=0.529; H3N2: p=0.570; influenza B: p=0.401) 
(Table 6).
DISCUSSION
Annual vaccination is recommended by WHO as the 
most effective way of preventing seasonal influenza. In 
Brazil, the National Immunization Program of the Ministry 
of Health has carried out annual national influenza vaccine 
campaigns since 1999. Currently, IB is one of the main 
public producers of seasonal trivalent influenza vaccine 
(inactivated split-virion) in the world and has delivered it to 
the annual influenza vaccination campaign of the National 
Immunization Program.
From 2013 to 2015, the Brazilian Regulatory Health 
Authority (Agência Nacional de Vigilância Sanitária 
- ANVISA) requested IB to perform post-licensure 
prospective cohort studies to evaluate the safety and 
immunogenicity of the 2013, 2014, and 2015 seasonal 
influenza vaccines in health adults and people over 60 
years of age. The sample size for each annual study was 
established in accordance with ANVISA and followed 
the EMA’s recommendations for clinical evaluation 
of trivalent seasonal influenza vaccine. The number of 
participants in the 2013 study was lower compared to 
the number of participants in the 2014 and 2015 studies. 
However, this did not affect the results because the safety 
and immunogenicity data described for the three years 
were similar. This confirms that post-licensure surveillance 
(pharmacovigilance activities) is more appropriate for 
the detection of rare or unexpected safety signals and 
effectiveness data of the seasonal influenza vaccines and 






p*<1:40 ≥1:40 <1:40 ≥1:40
n (CI 95%) n (CI 95%) n (CI 95%) n (CI 95%)
2013 Study
GMTR           
H1N1 21 13.6 (7.9-23.4) 21 2.1 (1.6-2.8) <0.001 6 25.4 (9.4-68.6) 7 3.3 (1.6-6.7) 0.009
H3N2 21 15.0 (8.5-26.5) 21 6.1 (3.8-10.0) 0.023 9 16.0 (5.5-46.4) 4 2.0 (2.0-2.0) 0.011
B 21 5.9 (4.4-8.0) 21 2.2 (1.5-3.3) <0.001 9 5.4 (2.7-11.1) 4 2.8 (0.4-19.1) 0.337
SCR           
H1N1 21 90.5% (69.6-98.8) 21 23.8% (8.2-47.2) <0.001 6 100% (54.1-100) 7 57.1% (18.4-90.1) 0.192
H3N2 21 85.7% (63.7-97.0) 21 71.4% (47.8-88.7) 0.454 9 88.9% (51.8-99.7) 4 0.0% (0.0-60.2) 0.007
B 21 76.2% (52.8-91.8) 21 28.6% (11.3-52.2) 0.005 9 77.8% (40.0-97.2) 4 50.0% (6.8-93.2) 0.530
2014 Study
GMTR           
H1N1 9 4.3 (2.6-7.1) 48 2.3 (2.0-2.8) 0.011 25 5.6 (3.8-8.2) 33 3.0 (2.2-4.0) 0.005
H3N2 13 9.4 (4.0-22.1) 44 2.0 (1.7-2.3) <0.001 11 10.3 (3.9-26.9) 47 2.2 (1.8-2.7) <0.001
B 7 8.0 (2.5-25.8) 50 1.9 (1.6-2.2) <0.001 15 4.6 (2.7-7.9) 43 2.3 (1.8-3.0) 0.010
SCR           
H1N1 9 66.7% (29.9-92.5) 48 33.3% (20.4-48.4) 0.075 25 68.0% (46.5-85.1) 33 33.3% (18.0-51.8) 0.016
H3N2 13 69.2% (38.6-90.9) 44 20.5% (9.8-35.3) 0.002 11 81.8% (48.2-97.7) 47 27.7% (15.6-42.6) 0.001
B 7 71.4% (29.0-96.3) 50 10.0% (3.3-21.8) 0.001 15 66.7% (38.4-88.2) 43 27.9% (15.3-43.7) 0.013
2015 Study
GMTR           
H1N1 13 3.8 (2.0-7.3) 46 1.6 (1.4-1.9) 0.002 34 2.9 (2.3-3.7) 22 2.0 (1.6-2.5) 0.044
H3N2 25 10.6 (7.5-14.8) 34 3.4 (2.4-4.8) <0.001 29 8.0 (5.5-11.7) 27 4.7 (3.1-7.0) 0.053
B 7 3.3 (1.4-7.9) 52 1.6 (1.4-1.9) 0.028 21 3.7 (2.5-5.6) 35 2.1 (1.6-2.7) 0.014
SCR           
H1N1 13 38.5% (13.9-68.4) 46 8.7% (2.4-20.8) 0.019 34 29.4% (15.1-47.5) 22 18.2% (5.2-40.3) 0.529
H3N2 25 96.0% (79.6-99.9) 34 55.9% (37.9-72.8) 0.001 29 72.4% (52.8-87.3) 27 63.0% (42.4-80.6) 0.570
B 7 42.9% (9.9-81.6) 52 9.6% (3.2-21.0) 0.046 21 47.6% (25.7-70.2) 35 34.3% (19.1-52.2) 0.401
Abbreviations: GMTR, Geometric Mean Titer Ratio; SCR, Seroconversion Rate. (*) Mann-Whitney test for GMTR and Fisher's exact test for SCR
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they should be obtained through classic efficacy trials and 
not be based only on immunogenicity data.
Among the strategies of the Division of Clinical Trials 
and Pharmacovigilance of IB for conducting clinical 
studies with immunobiological products produced by 
the IB is the establishment of partnerships with national 
institutions linked to the Unified Health System (SUS), 
such as Brazilian universities and the Adolfo Lutz Institute. 
These partnerships have made it possible to integrate 
basic immunobiological research, vaccine development 
and production, and clinical studies, thus completing the 
innovation process characterized by the availability of 
vaccines produced by Brazilian public laboratories for SUS. 
The 2013, 2014 and 2015 influenza vaccine studies 
included the participation of the Adolfo Lutz Institute, the 
CRIE-HCFMUSP and ICR-HCFMUSP. The total number 
of participants in the three studies was 299: 60 in 2013; 120 
in 2014; and 119 in 2015. The 2013 study was the one with 
the lowest number of participants (47 adults and 13 elderly) 
probably due to the late start of the study in the clinical site 
when the influenza annual immunization campaign was 
already close to the end.
Overall, the vaccines were well-tolerated with no 
unexpected events or new safety signals. Only in the 2014 
and 2015 studies, the incidence of adverse reactions was 
statistically higher in adults when compared to the elderly. 
The adverse reactions observed in adults and elderly, in the 
three studies, were classified as mild or moderate, and no 
severe adverse reaction was reported. Besides, they were 
predominantly observed within 24 h after vaccination and 
disappeared up to seven days. These findings have also been 
demonstrated for other trivalent seasonal influenza vaccines 
(split-virion, inactivated)12,13.
The most frequent adverse reactions, in the three studies, 
were local pain at the injection site and headache, both in 
adults and in the elderly. These adverse reactions have also 
been described in the literature for other trivalent seasonal 
influenza vaccines (split-virion, inactivated)14-17. Fever 
had a low incidence in the three studies; it is known to be 
associated with trivalent inactivated influenza vaccines 
but is not considered a serious event nor is associated with 
complications18.
According to EMA’s recommendations7,8, trivalent 
seasonal influenza vaccine (split-virion inactivated) is 
considered immunogenic when one of the following 
parameters is demonstrated: a) in adults: SCR >40% 
and/or SPR >70%, and/or HI antibody GMTR >2.5; b) in the 
elderly: SCR >30% and/or SPR >60% and/or HI antibody 
GMTR >2.0.
In 2013, the vaccine immunogenicity in adults was 
demonstrated for the three vaccine viruses by SPR >70%, 
SCR >40% and GMTR >2.5; in 2014, by SPR >70%; and 
in 2015 by SPR >70%. For the elderly, in 2013 and 2014 
the vaccine immunogenicity was demonstrated for the three 
vaccine by SPR >60%, SCR >30% and GMTR >2.0; and 
in 2015 by SPR >60% and GMTR >2.0. 
Surprisingly, adequate seroconversion frequency values 
 were not observed for the three vaccine viruses among 
adults in the 2014 study and specifically for the H1N1 and 
influenza B viruses in the 2015 study. However, when one 
analyses the frequency of seroconversion in the 2014 study 
among adults, significantly higher values  of this frequency 
were observed for H3N2 and influenza B vaccine viruses 
among participants who had pre-immunization HI antibodies 
titers <1:40 compared to those with pre-immunization HI 
antibodies titers ≥1:40. Furthermore, the frequency of 
seroconversion ended up being greater than 40% among 
those with pre-immunization HI antibodies titers <1:40. 
In the 2015 study, significantly higher seroconversion rates 
were also observed for H1N1 and influenza B vaccine 
viruses in adults with pre-immunization HI antibodies 
titers <1:40 compared to those with pre-immunization 
HI antibodies titers =1: 40. However, a frequency of 
seroconversion > 40% for the H1N1 vaccine virus among 
adults with pre-immunization HI antibodies titers <1:40 
antibody was not observed. These findings suggest that, in 
adults, the level of pre-immunization HI antibodies may 
impact on the frequency of seroconversion to influenza 
vaccination and that this impact is strain-specific.
CONCLUSION
The results of this study demonstrated that the 2013, 
2014 and 2015 seasonal influenza vaccines (inactivated 
split-virion) produced integrally by the IB were overall well-
tolerated and safe, since no unexpected events or new safety 
signs were observed. In addition, these vaccines have been 
shown to be immunogenic based on the immunogenicity 
criteria defined by the EMA. The satisfactory safety and 
immunogenicity profiles demonstrated over the three study 
years confirmed the production consistency of the seasonal 
influenza vaccine (inactivated split-virion) by the IB.
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